Data Insights

NX-1607 by Nurix Therapeutics for Cervical Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Cervical Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Gastric Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Gastric Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Diffuse Large B-Cell Lymphoma

Data Insights

NX-1607 by Nurix Therapeutics for Metastatic Melanoma: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Metastatic Melanoma

Data Insights

NX-1607 by Nurix Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Non-Small Cell Lung Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Fallopian Tube Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Fallopian Tube Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

NX-1607 by Nurix Therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Malignant Pleural Mesothelioma

Data Insights

NX-1607 by Nurix Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Metastatic Colorectal Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Peritoneal Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Peritoneal Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Epithelial Ovarian Cancer

Data Insights

NX-1607 by Nurix Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

NX-1607 by Nurix Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Triple-Negative Breast Cancer (TNBC)

Data Insights

NX-1607 by Nurix Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - NX-1607 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Risk adjusted net present value: What is the current valuation of Nurix Therapeutics's NX-1607?

NX-1607 is a small molecule commercialized by Nurix Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...

Net Present Value Model: Nurix Therapeutics Inc's NX-1607